A patient's self-reported data can be incomplete or biased, as they may only report the "good measures." To get the full picture, companies must gather input from multiple sources, like caregivers and clinicians. Each perspective helps correct the others, creating a more accurate and holistic view of the patient's journey.

The biggest limitation in precision medicine is the systemic failure to capture and learn from longitudinal data on how patients respond to treatments over time. Without this critical feedback loop, even the most sophisticated diagnostic models will fall short of their potential to improve care.

Advanced AI models are ineffective in clinical settings without a robust data layer. Ambience had to solve fundamental problems like pulling messy context from inconsistent EHRs and preserving 'decision traces,' which are often destroyed by existing systems with mutable data structures.

The effectiveness of AI and machine learning models for predicting patient behavior hinges entirely on the quality of the underlying real-world data. Walgreens emphasizes its investment in data synthesis and validation as the non-negotiable prerequisite for generating actionable insights.

Existing healthcare datasets like claims are flawed proxies. The most valuable, untapped data will come from new sources like AI scribe encounters and patient-uploaded data into modern PHRs. This 'ground truth' data will unlock novel applications like usage-based malpractice insurance.

Rather than forcing thousands of global hospitals to adopt uniform instruments or protocols, Sophia Genetics' platform is built to work across this complexity. This approach supports wider adoption and turns the challenge of diverse data sources into a strength for building robust, generalizable AI models.

To truly understand biological systems, data scale is less important than data quality. The most informative data comes from capturing the dynamic interactions of a system *while* it's being perturbed (e.g., by a drug), not from static snapshots of a system at rest.

Contrary to the norm where real-world outcomes are worse than in controlled trials, real-world data for the oral SERD elacestrant shows efficacy as good as, or even better than, the pivotal EMERALD study. This unusual finding significantly bolsters confidence in the drug's broad clinical utility across a less-selected patient population.

Industry leaders often believe their clinical trial designs are patient-centric, but direct experience in community clinics reveals the significant burden placed on patients and caregivers, such as 12-hour blood draw days. This exposure leads to more practical and humane trial designs that improve real-world data collection.